person · Reporting owner

Powell Andrew Kenneth William

Disclosed activity across 5 companies

Tapewire entity: 90276
SEC CIK: 0001304113

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
ARS Pharmaceuticals, Inc.SBTX · Entity 883	Director	June 10, 2022	June 13, 2022
Aclaris Therapeutics, Inc.ACRS · Entity 5041	Director	June 01, 2024	June 04, 2024
LIFECORE BIOMEDICAL, INC. \DE\LNDC · Entity 6447	Director	June 04, 2022	June 07, 2022

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ARS Pharmaceuticals, Inc.

Report date June 10, 2022 · Filed June 13, 2022

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.18 · Expires 2032-06-09	Direct	18,000	Reported balance After 2022-06-10 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2022-06-10 · Grant · Acquired 18,000 · Balance 18,000 F1: The shares subject to the option vest on the earlier of June 10, 2023 or the date of the Issuer's 2023 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors.

Filing footnotes · ownership attribution and instrument terms

F1: The shares subject to the option vest on the earlier of June 10, 2023 or the date of the Issuer's 2023 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors.

Aclaris Therapeutics, Inc.

Report date June 01, 2024 · Filed June 04, 2024

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	33,523	Reported balance After 2024-06-01 transaction · row 1 1 source row Row 1 · 2024-06-01 · Exercise / conversion · Acquired 4,660 · Balance 33,523 F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2024-06-01 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2024-06-01 · Exercise / conversion · Disposed 4,660 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F2: The shares underlying these restricted stock units vested on June 1, 2024.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.

F2: The shares underlying these restricted stock units vested on June 1, 2024.

LIFECORE BIOMEDICAL, INC. \DE\

Report date June 04, 2022 · Filed June 07, 2022

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	27,477	Reported balance After 2022-06-04 transaction · row 1 1 source row Row 1 · 2022-06-04 · Grant · Acquired 7,059 · Balance 27,477 F1: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis.
Restricted Stock UnitSEC Table II · derivative / convertible security · Expires 2022-06-04	Direct	0	Reported balance After 2022-06-04 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2022-06-04 · Exercise / conversion · Disposed 7,059 · Balance 0 F1: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis. F2: The restricted stock units were granted on June 4, 2021. F3: The restricted stock units vested on June 4, 2022.

Filing footnotes · ownership attribution and instrument terms

F1: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis.

F2: The restricted stock units were granted on June 4, 2021.

F3: The restricted stock units vested on June 4, 2022.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

MEDIVATION, INC.

Report date September 28, 2016 · Filed September 30, 2016

Section 16 reporting ended · disclosed 2016-09-30. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2016-09-28 transaction · row 1 Sequence does not reconcile; account continuity is unresolved. 1 source row Row 1 · 2016-09-28 · Other · Disposed 5,597 · Balance 0 F1: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated August 20, 2016, among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Montreal, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent ("Purchaser"), in exchange for a cash consideration of $81.50 per share (without interest) subject to any required withholding of taxes. Pursuant to the Merger Agreement, the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent (the "Merger"). In connection with the Merger, Purchaser offered to purchase all of the outstanding shares of common stock, par value $0.01 per share of the Issuer, at a price of $81.50 per share, net to the seller in cash (without interest) but subject to any required withholding of taxes, upon the terms and conditions set forth in the offer to purchase dated August 30, 2016, and in the related letter of transmittal.
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2016-09-28 transaction · row 2 Sequence does not reconcile; account continuity is unresolved. 1 source row Row 2 · 2016-09-28 · Disposition to issuer · Disposed 22,920 · Balance 0 F1: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated August 20, 2016, among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Montreal, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent ("Purchaser"), in exchange for a cash consideration of $81.50 per share (without interest) subject to any required withholding of taxes. Pursuant to the Merger Agreement, the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent (the "Merger"). In connection with the Merger, Purchaser offered to purchase all of the outstanding shares of common stock, par value $0.01 per share of the Issuer, at a price of $81.50 per share, net to the seller in cash (without interest) but subject to any required withholding of taxes, upon the terms and conditions set forth in the offer to purchase dated August 30, 2016, and in the related letter of transmittal. F2: Represents unvested restricted stock units (the "RSUs") that were cancelled in the Merger and, in lieu of any issuance of shares in settlement of such RSUs, converted into the right to receive cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes. In connection with the Merger, vesting of the RSUs was accelerated and the RSUs became fully vested effective immediately prior to the effective time of the Merger.
Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $64.17 · Expires 2025-06-01	Direct	Reported balance After 2016-09-28 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2016-09-28 · Disposition to issuer · Disposed 40,860 · Balance 0 F3: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger.
Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.77 · Expires 2026-02-28	Direct	Reported balance After 2016-09-28 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2016-09-28 · Disposition to issuer · Disposed 38,530 · Balance 0 F3: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger.
Performance-Based Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2020-02-18	Direct	Reported balance After 2016-09-28 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2016-09-28 · Disposition to issuer · Disposed 14,474 · Balance 0 F4: The number of shares subject to the performance-based restricted stock unit (the "PSUs") is based on deemed satisfaction of all applicable performance goals at the maximum levels. F5: The PSUs were cancelled in the Merger and, in lieu of any issuance of shares in settlement of such PSUs, converted into the right to receive cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes. In connection with the Merger, vesting of the PSUs was accelerated and the PSUs became fully vested effective immediately prior to the effective time of the Merger.

Filing footnotes · ownership attribution and instrument terms

F1: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated August 20, 2016, among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Montreal, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent ("Purchaser"), in exchange for a cash consideration of $81.50 per share (without interest) subject to any required withholding of taxes. Pursuant to the Merger Agreement, the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent (the "Merger"). In connection with the Merger, Purchaser offered to purchase all of the outstanding shares of common stock, par value $0.01 per share of the Issuer, at a price of $81.50 per share, net to the seller in cash (without interest) but subject to any required withholding of taxes, upon the terms and conditions set forth in the offer to purchase dated August 30, 2016, and in the related letter of transmittal.

F2: Represents unvested restricted stock units (the "RSUs") that were cancelled in the Merger and, in lieu of any issuance of shares in settlement of such RSUs, converted into the right to receive cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes. In connection with the Merger, vesting of the RSUs was accelerated and the RSUs became fully vested effective immediately prior to the effective time of the Merger.

F3: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger.

F4: The number of shares subject to the performance-based restricted stock unit (the "PSUs") is based on deemed satisfaction of all applicable performance goals at the maximum levels.

F5: The PSUs were cancelled in the Merger and, in lieu of any issuance of shares in settlement of such PSUs, converted into the right to receive cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes. In connection with the Merger, vesting of the PSUs was accelerated and the PSUs became fully vested effective immediately prior to the effective time of the Merger.

Synthorx, Inc.

Report date January 23, 2020 · Filed January 24, 2020

Section 16 reporting ended · disclosed 2020-01-24. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.00 · Expires 2028-12-18	Direct	0	Reported balance After 2020-01-23 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2020-01-23 · Disposition to issuer · Disposed 27,015 · Balance 0 F1: This option, which provided for vesting of the shares in equal monthly installments over a three year period such that the option would be fully vested on December 19, 2021, was cancelled in connection with the merger of the Issuer with Sanofi's wholly owned subsidiary in exchange for a cash payment of $1,458,810.00, representing the difference between the exercise price of the option and the market value of the underlying common stock of the Issuer on the effective date of the merger ($68).
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.40 · Expires 2029-06-06	Direct	0	Reported balance After 2020-01-23 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2020-01-23 · Disposition to issuer · Disposed 6,389 · Balance 0 F2: This option, which provided for vesting of the shares in equal monthly installments over the 12 months following June 7, 2019, such that the option would be fully vested on the date of the Issuer's next annual stockholder meeting, was cancelled in connection with the merger of the Issuer with Sanofi's wholly owned subsidiary in exchange for a cash payment of $355,228.40, representing the difference between the exercise price of the option and the market value of the underlying common stock of the Issuer on the effective date of the merger ($68).

Filing footnotes · ownership attribution and instrument terms

F1: This option, which provided for vesting of the shares in equal monthly installments over a three year period such that the option would be fully vested on December 19, 2021, was cancelled in connection with the merger of the Issuer with Sanofi's wholly owned subsidiary in exchange for a cash payment of $1,458,810.00, representing the difference between the exercise price of the option and the market value of the underlying common stock of the Issuer on the effective date of the merger ($68).

F2: This option, which provided for vesting of the shares in equal monthly installments over the 12 months following June 7, 2019, such that the option would be fully vested on the date of the Issuer's next annual stockholder meeting, was cancelled in connection with the merger of the Issuer with Sanofi's wholly owned subsidiary in exchange for a cash payment of $355,228.40, representing the difference between the exercise price of the option and the market value of the underlying common stock of the Issuer on the effective date of the merger ($68).

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 01, 2024 Filed Jun 4, 2024 16:30 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	Exercise / conversionRestricted Stock Units · Derivative	4,660	$0.00	$0.00	Disclosure SEC source: 0001415889-24-015368 · form4-06042024_040616.xml · derivative · entry 2 Powell Andrew Kenneth William · CIK 0001304113 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,660 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F2 · derivative.exercise_date: The shares underlying these restricted stock units vested on June 1, 2024. F2 · derivative.expiration_date: The shares underlying these restricted stock units vested on June 1, 2024. Read SEC document
June 01, 2024 Filed Jun 4, 2024 16:30 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	Exercise / conversionCommon Stock	4,660	Not disclosed	Not disclosed	Disclosure SEC source: 0001415889-24-015368 · form4-06042024_040616.xml · nonDerivative · entry 1 Powell Andrew Kenneth William · CIK 0001304113 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,523 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document
March 04, 2024 Filed Mar 5, 2024 16:58 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	PurchaseCommon Stock	6,000	$1.25	$7,500.00	Disclosure SEC source: 0001209191-24-004385 · doc4.xml · nonDerivative · entry 2 Powell Andrew Kenneth William · CIK 0001304113 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,863 F2 · price: The price reported is a weighted average purchase price. The shares were purchased in multiple transactions at prices ranging from $1.230 to $1.269, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document
March 01, 2024 Filed Mar 5, 2024 16:58 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	PurchaseCommon Stock	8,500	$1.23	$10,455.00	Disclosure SEC source: 0001209191-24-004385 · doc4.xml · nonDerivative · entry 1 Powell Andrew Kenneth William · CIK 0001304113 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,863 F1 · price: The price reported is a weighted average purchase price. The shares were purchased in multiple transactions at prices ranging from $1.230 to $1.2393, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document
June 02, 2023 Filed Jun 5, 2023 16:50 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	Exercise / conversionRestricted Stock Units · Derivative	4,507	$0.00	$0.00	Disclosure SEC source: 0001209191-23-034399 · doc4.xml · derivative · entry 4 Powell Andrew Kenneth William · CIK 0001304113 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,507 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F5 · derivative.exercise_date: The shares underlying these restricted stock units vested on June 2, 2023. F5 · derivative.expiration_date: The shares underlying these restricted stock units vested on June 2, 2023. Read SEC document
June 02, 2023 Filed Jun 5, 2023 16:50 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	Exercise / conversionCommon Stock	4,507	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-23-034399 · doc4.xml · nonDerivative · entry 1 Powell Andrew Kenneth William · CIK 0001304113 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,363 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document
June 01, 2023 Filed Jun 5, 2023 16:50 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	GrantRestricted Stock Units · Derivative	4,660	$0.00	$0.00	Disclosure SEC source: 0001209191-23-034399 · doc4.xml · derivative · entry 3 Powell Andrew Kenneth William · CIK 0001304113 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,660 Underlying: Common Stock · 4,660 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F2 · derivative.exercise_date: This grant was made pursuant to the issuer's ninth amended and restated non-employee director compensation policy. F4 · derivative.exercise_date: The shares underlying these restricted stock units will vest on June 1, 2024, subject to the Reporting Person's continuous service through such date. F4 · derivative.expiration_date: The shares underlying these restricted stock units will vest on June 1, 2024, subject to the Reporting Person's continuous service through such date. Read SEC document
June 01, 2023 Filed Jun 5, 2023 16:50 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	GrantStock Option (Right to Buy) · Derivative	15,750	$0.00 Strike: $8.70	$0.00	Disclosure SEC source: 0001209191-23-034399 · doc4.xml · derivative · entry 2 Powell Andrew Kenneth William · CIK 0001304113 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,750 Underlying: Common Stock · 15,750 shares Expires 2033-05-31 F2 · derivative.exercise_date: This grant was made pursuant to the issuer's ninth amended and restated non-employee director compensation policy. F3 · derivative.exercise_date: The shares subject to this option will vest in twelve equal monthly installments commencing July 1, 2023, subject to Reporting Person's continuous service through each such date. Read SEC document
November 08, 2022 Filed Jan 20, 2023 17:08 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	GiftCommon Stock	4,000	$0.00	$0.00	Disclosure SEC source: 0001209191-23-004300 · doc4.xml · nonDerivative · entry 1 Powell Andrew Kenneth William · CIK 0001304113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,856 Read SEC document
June 10, 2022 Filed Jun 13, 2022 23:44 UTC	ARS Pharmaceuticals, Inc. SBTX · Entity 883	GrantStock Option (right to buy) · Derivative	18,000	$0.00 Strike: $4.18	$0.00	Disclosure SEC source: 0001209191-22-036476 · doc4.xml · derivative · entry 1 Powell Andrew Kenneth William · CIK 0001304113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2032-06-09 F1 · derivative.exercise_date: The shares subject to the option vest on the earlier of June 10, 2023 or the date of the Issuer's 2023 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors. Read SEC document
June 04, 2022 Filed Jun 7, 2022 21:18 UTC	LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447	Exercise / conversionRestricted Stock Unit · Derivative	7,059	$9.50	$67,060.50	Disclosure SEC source: 0001628280-22-016491 · wf-form4_165463670638202.xml · derivative · entry 2 Powell Andrew Kenneth William · CIK 0001304113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,059 shares Expires 2022-06-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis. F2 · shares: The restricted stock units were granted on June 4, 2021. F3 · derivative.exercise_date: The restricted stock units vested on June 4, 2022. F3 · derivative.expiration_date: The restricted stock units vested on June 4, 2022. Read SEC document
June 04, 2022 Filed Jun 7, 2022 21:18 UTC	LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447	GrantCommon Stock	7,059	$9.50	$67,060.50	Disclosure SEC source: 0001628280-22-016491 · wf-form4_165463670638202.xml · nonDerivative · entry 1 Powell Andrew Kenneth William · CIK 0001304113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,477 F1 · price: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis. Read SEC document
June 03, 2022 Filed Jun 6, 2022 17:30 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	Exercise / conversionRestricted Stock Units · Derivative	3,356	$0.00	$0.00	Disclosure SEC source: 0001209191-22-034601 · doc4.xml · derivative · entry 5 Powell Andrew Kenneth William · CIK 0001304113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,356 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F5 · derivative.exercise_date: The shares underlying these restricted stock units vested on June 3, 2022. F5 · derivative.expiration_date: The shares underlying these restricted stock units vested on June 3, 2022. Read SEC document
June 03, 2022 Filed Jun 6, 2022 17:30 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	Exercise / conversionCommon Stock	3,356	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-22-034601 · doc4.xml · nonDerivative · entry 2 Powell Andrew Kenneth William · CIK 0001304113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,856 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document
June 02, 2022 Filed Jun 6, 2022 17:30 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	GrantRestricted Stock Units · Derivative	4,507	$0.00	$0.00	Disclosure SEC source: 0001209191-22-034601 · doc4.xml · derivative · entry 4 Powell Andrew Kenneth William · CIK 0001304113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,507 Underlying: Common Stock · 4,507 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F2 · derivative.exercise_date: This grant was made pursuant to the issuer's seventh amended and restated non-employee director compensation policy. F4 · derivative.exercise_date: The shares underlying these restricted stock units will vest on June 2, 2023, subject to the Reporting Person's continuous service through such date. F4 · derivative.expiration_date: The shares underlying these restricted stock units will vest on June 2, 2023, subject to the Reporting Person's continuous service through such date. Read SEC document
June 02, 2022 Filed Jun 6, 2022 17:30 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	GrantStock Option (Right to Buy) · Derivative	15,750	$0.00 Strike: $14.48	$0.00	Disclosure SEC source: 0001209191-22-034601 · doc4.xml · derivative · entry 3 Powell Andrew Kenneth William · CIK 0001304113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,750 Underlying: Common Stock · 15,750 shares Expires 2032-06-01 F2 · derivative.exercise_date: This grant was made pursuant to the issuer's seventh amended and restated non-employee director compensation policy. F3 · derivative.exercise_date: The shares subject to this option will vest in twelve equal monthly installments commencing July 2, 2022, subject to Reporting Person's continuous service through each such date. Read SEC document
May 31, 2022 Filed Jun 2, 2022 16:45 UTC	LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447	GrantRestricted Stock Unit · Derivative	9,474	Not disclosed	Not disclosed	Disclosure SEC source: 0001628280-22-016006 · wf-form4_165418829909139.xml · derivative · entry 1 Powell Andrew Kenneth William · CIK 0001304113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,474 Underlying: Common Stock · 9,474 shares Expires not disclosed F1 · derivative.exercise_price: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis. F1 · price: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis. F2 · derivative.expiration_date: Restricted Stock Units will vest on the 1st anniversary of the grant date and will be automatically settled in shares of common stock. Read SEC document
May 16, 2022 Filed Jun 6, 2022 17:30 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	GiftCommon Stock	709	$0.00	$0.00	Disclosure SEC source: 0001209191-22-034601 · doc4.xml · nonDerivative · entry 1 Powell Andrew Kenneth William · CIK 0001304113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,500 Read SEC document
November 23, 2021 Filed Dec 3, 2021 16:52 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	GiftCommon Stock	5,500	$0.00	$0.00	Disclosure SEC source: 0001209191-21-067863 · doc4.xml · nonDerivative · entry 1 Powell Andrew Kenneth William · CIK 0001304113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,209 Read SEC document
June 04, 2021 Filed Jun 9, 2021 00:01 UTC	LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447	GrantRestricted Stock Unit · Derivative	7,059	Not disclosed	Not disclosed	Disclosure SEC source: 0001593968-21-001570 · primary_01.xml · derivative · entry 1 Powell Andrew Kenneth William · CIK 0001304113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,059 Underlying: Common Stock · 7,059 shares Expires not disclosed F1 · derivative.exercise_price: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis. F1 · price: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis. F2 · derivative.expiration_date: Restricted Stock Units will vest on the 1st anniversary of the grant date and will be automatically settled in shares of common stock. Read SEC document
June 04, 2021 Filed Sep 21, 2021 21:08 UTC	ARS Pharmaceuticals, Inc. SBTX · Entity 883	GrantStock Option (right to buy) · Derivative	15,000	$0.00 Strike: $28.83	$0.00	Disclosure SEC source: 0001209191-21-057061 · doc4.xml · derivative · entry 1 Powell Andrew Kenneth William · CIK 0001304113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2031-06-03 F1 · derivative.exercise_date: The shares subject to the option vest on the earlier of June 4, 2022 or the date of the 2022 annual meeting of the Issuer's stockholders which date has not been set by the Issuer's Board of Directors. Read SEC document
June 03, 2021 Filed Jun 4, 2021 20:07 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	GrantRestricted Stock Units · Derivative	3,356	$0.00	$0.00	Disclosure SEC source: 0001209191-21-038455 · doc4.xml · derivative · entry 2 Powell Andrew Kenneth William · CIK 0001304113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,356 Underlying: Common Stock · 3,356 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F1 · derivative.exercise_date: This grant was made pursuant to the issuer's fifth amended and restated non-employee director compensation policy. F4 · derivative.exercise_date: The shares underlying these restricted stock units will vest on June 3, 2022, subject to the Reporting Person's continuous service through such date. F4 · derivative.expiration_date: The shares underlying these restricted stock units will vest on June 3, 2022, subject to the Reporting Person's continuous service through such date. Read SEC document
June 03, 2021 Filed Jun 4, 2021 20:07 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	GrantStock Option (Right to Buy) · Derivative	12,250	$0.00 Strike: $21.90	$0.00	Disclosure SEC source: 0001209191-21-038455 · doc4.xml · derivative · entry 1 Powell Andrew Kenneth William · CIK 0001304113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,250 Underlying: Common Stock · 12,250 shares Expires 2031-06-02 F1 · derivative.exercise_date: This grant was made pursuant to the issuer's fifth amended and restated non-employee director compensation policy. F2 · derivative.exercise_date: The shares subject this option will vest in twelve equal monthly installments commencing July 3, 2021, subject to Reporting Person's continuous service through each such date. Read SEC document
June 01, 2021 Filed Jun 4, 2021 00:02 UTC	LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447	Exercise / conversionRestricted Stock Unit · Derivative	8,303	$11.64	$96,646.92	Disclosure SEC source: 0001593968-21-001521 · primary_01.xml · derivative · entry 2 Powell Andrew Kenneth William · CIK 0001304113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,303 shares Expires 2021-06-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis. F2 · shares: The restricted stock units were granted on June 1, 2020. F3 · derivative.exercise_date: The restricted stock units vested on June 1, 2021. F3 · derivative.expiration_date: The restricted stock units vested on June 1, 2021. Read SEC document
June 01, 2021 Filed Jun 4, 2021 00:02 UTC	LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447	GrantCommon Stock	8,303	$11.64	$96,646.92	Disclosure SEC source: 0001593968-21-001521 · primary_01.xml · nonDerivative · entry 1 Powell Andrew Kenneth William · CIK 0001304113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,418 F1 · price: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis. Read SEC document
December 03, 2020 Filed Dec 8, 2020 00:56 UTC	ARS Pharmaceuticals, Inc. SBTX · Entity 883	GrantStock Option (right to buy) · Derivative	21,009	$0.00 Strike: $21.00	$0.00	Disclosure SEC source: 0001209191-20-062050 · doc4.xml · derivative · entry 1 Powell Andrew Kenneth William · CIK 0001304113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,009 Underlying: Common Stock · 21,009 shares Expires 2030-12-02 F1 · derivative.exercise_date: The shares subject to the option vest in equal monthly installments over the 36 months following December 3, 2020. Read SEC document
October 15, 2020 Filed Oct 19, 2020 20:17 UTC	LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447	Exercise / conversionRestricted Stock Unit · Derivative	2,200	$0.00	$0.00	Disclosure SEC source: 0001593968-20-002069 · primary_01.xml · derivative · entry 2 Powell Andrew Kenneth William · CIK 0001304113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,200 shares Expires 2020-10-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis. F2 · shares: The restricted stock units were granted on October 15, 2019. F3 · derivative.exercise_date: The restricted stock units vested on October 15, 2020. F3 · derivative.expiration_date: The restricted stock units vested on October 15, 2020. Read SEC document
October 15, 2020 Filed Oct 19, 2020 20:17 UTC	LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447	GrantCommon Stock	2,200	$10.36	$22,792.00	Disclosure SEC source: 0001593968-20-002069 · primary_01.xml · nonDerivative · entry 1 Powell Andrew Kenneth William · CIK 0001304113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,115 F1 · price: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis. Read SEC document
June 06, 2020 Filed Jun 8, 2020 17:28 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	Exercise / conversionRestricted Stock Units · Derivative	7,333	$0.00	$0.00	Disclosure SEC source: 0001209191-20-035031 · doc4.xml · derivative · entry 3 Powell Andrew Kenneth William · CIK 0001304113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F3 · shares: This grant was made pursuant to the issuer's amended and restated non-employee director compensation policy. F4 · derivative.exercise_date: The shares underlying these restricted stock units vested on June 6, 2020. F4 · derivative.expiration_date: The shares underlying these restricted stock units vested on June 6, 2020. Read SEC document
June 06, 2020 Filed Jun 8, 2020 17:28 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	Exercise / conversionCommon Stock	7,333	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-20-035031 · doc4.xml · nonDerivative · entry 1 Powell Andrew Kenneth William · CIK 0001304113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,709 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document
June 04, 2020 Filed Jun 8, 2020 17:28 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	GrantOption Grant (right to buy) · Derivative	16,500	$0.00 Strike: $1.41	$0.00	Disclosure SEC source: 0001209191-20-035031 · doc4.xml · derivative · entry 2 Powell Andrew Kenneth William · CIK 0001304113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Stock · 16,500 shares Expires 2030-06-03 F2 · derivative.exercise_date: The shares subject this option will vest in twelve equal monthly installments commencing July 4, 2020, subject to Reporting Person's continuous service through each such date. Read SEC document
June 01, 2020 Filed Jun 2, 2020 22:23 UTC	LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447	GrantRight to Buy Restricted Stock Unit (RSU) · Derivative	8,303	Not disclosed	Not disclosed	Disclosure SEC source: 0001628280-20-008848 · wf-form4_159113661548632.xml · derivative · entry 1 Powell Andrew Kenneth William · CIK 0001304113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,303 Underlying: Common Stock · 8,303 shares Expires not disclosed F1 · derivative.exercise_price: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis. F1 · price: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis. F2 · derivative.expiration_date: Restricted Stock Units will vest on the 1st anniversary of the grant date and will be automatically settled in shares of common stock. Read SEC document
May 28, 2020 Filed May 29, 2020 19:46 UTC	LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447	Exercise / conversionRestricted Stock Unit · Derivative	6,000	$0.00	$0.00	Disclosure SEC source: 0001628280-20-008622 · wf-form4_159078159558808.xml · derivative · entry 2 Powell Andrew Kenneth William · CIK 0001304113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,000 shares Expires 2020-05-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis. F2 · shares: The restricted stock units were granted on May 28, 2019. F3 · derivative.exercise_date: The restricted stock units vested on May 28, 2020. F3 · derivative.expiration_date: The restricted stock units vested on May 28, 2020. Read SEC document
May 28, 2020 Filed May 29, 2020 19:46 UTC	LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447	GrantCommon Stock	6,000	$10.99	$65,940.00	Disclosure SEC source: 0001628280-20-008622 · wf-form4_159078159558808.xml · nonDerivative · entry 1 Powell Andrew Kenneth William · CIK 0001304113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,915 F1 · price: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis. Read SEC document
March 02, 2020 Filed Mar 4, 2020 16:27 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	Exercise / conversionRestricted stock units · Derivative	8,876	$0.00	$0.00	Disclosure SEC source: 0001209191-20-016086 · doc4.xml · derivative · entry 3 Powell Andrew Kenneth William · CIK 0001304113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,876 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F2 · derivative.exercise_date: The shares underlying these restricted stock units vest immediately. F2 · derivative.expiration_date: The shares underlying these restricted stock units vest immediately. Read SEC document
March 02, 2020 Filed Mar 4, 2020 16:27 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	GrantRestricted stock units · Derivative	8,876	$0.00	$0.00	Disclosure SEC source: 0001209191-20-016086 · doc4.xml · derivative · entry 2 Powell Andrew Kenneth William · CIK 0001304113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,876 Underlying: Common Stock · 8,876 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F2 · derivative.exercise_date: The shares underlying these restricted stock units vest immediately. F2 · derivative.expiration_date: The shares underlying these restricted stock units vest immediately. Read SEC document
March 02, 2020 Filed Mar 4, 2020 16:27 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	Exercise / conversionCommon Stock	8,876	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-20-016086 · doc4.xml · nonDerivative · entry 1 Powell Andrew Kenneth William · CIK 0001304113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,376 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document
January 23, 2020 Filed Jan 24, 2020 18:34 UTC	Synthorx, Inc. THOR · Entity 152202	Disposition to issuerStock Option (right to buy) · Derivative	6,389	$55.60 Strike: $12.40	$355,228.40	Disclosure SEC source: 0001209191-20-004926 · doc4.xml · derivative · entry 2 Powell Andrew Kenneth William · CIK 0001304113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,389 shares Expires 2029-06-06 F2 · derivative.exercise_date: This option, which provided for vesting of the shares in equal monthly installments over the 12 months following June 7, 2019, such that the option would be fully vested on the date of the Issuer's next annual stockholder meeting, was cancelled in connection with the merger of the Issuer with Sanofi's wholly owned subsidiary in exchange for a cash payment of $355,228.40, representing the difference between the exercise price of the option and the market value of the underlying common stock of the Issuer on the effective date of the merger ($68). Read SEC document
January 23, 2020 Filed Jan 24, 2020 18:34 UTC	Synthorx, Inc. THOR · Entity 152202	Disposition to issuerStock Option (right to buy) · Derivative	27,015	$54.00 Strike: $14.00	$1,458,810.00	Disclosure SEC source: 0001209191-20-004926 · doc4.xml · derivative · entry 1 Powell Andrew Kenneth William · CIK 0001304113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 27,015 shares Expires 2028-12-18 F1 · derivative.exercise_date: This option, which provided for vesting of the shares in equal monthly installments over a three year period such that the option would be fully vested on December 19, 2021, was cancelled in connection with the merger of the Issuer with Sanofi's wholly owned subsidiary in exchange for a cash payment of $1,458,810.00, representing the difference between the exercise price of the option and the market value of the underlying common stock of the Issuer on the effective date of the merger ($68). Read SEC document
October 15, 2019 Filed Oct 17, 2019 19:15 UTC	LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447	GrantRight to Buy Restricted Stock Unit (RSU) · Derivative	2,200	Not disclosed	Not disclosed	Disclosure SEC source: 0001628280-19-012371 · wf-form4_157133968967988.xml · derivative · entry 1 Powell Andrew Kenneth William · CIK 0001304113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,200 Underlying: Common Stock · 2,200 shares Expires not disclosed F1 · derivative.exercise_price: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis. F1 · price: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis. F2 · derivative.expiration_date: Restricted Stock Units will vest on the 1st anniversary of the grant date and will be automatically settled in shares of common stock. Read SEC document
June 07, 2019 Filed Jun 10, 2019 18:54 UTC	Synthorx, Inc. THOR · Entity 152202	GrantStock Option (right to buy) · Derivative	6,389	$0.00 Strike: $12.40	$0.00	Disclosure SEC source: 0001209191-19-035982 · doc4.xml · derivative · entry 1 Powell Andrew Kenneth William · CIK 0001304113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,389 Underlying: Common Stock · 6,389 shares Expires 2029-06-06 F1 · derivative.exercise_date: The shares subject to the option vest in equal monthly installments over the 12 months following June 7, 2019, provided that the option will be fully vested on the date of the Issuer's next annual stockholder meeting. Read SEC document
June 06, 2019 Filed Jun 10, 2019 16:51 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	GrantRestricted Stock Units · Derivative	7,333	$0.00	$0.00	Disclosure SEC source: 0001209191-19-035832 · doc4.xml · derivative · entry 1 Powell Andrew Kenneth William · CIK 0001304113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,333 Underlying: Common Stock · 7,333 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F2 · shares: This grant was made pursuant to the issuer's amended and restated non-employee director compensation policy. F3 · derivative.exercise_date: The shares underlying these restricted stock units vest on June 6, 2020, subject to the Reporting Person's continuous service with the issuer as of the vesting date. F3 · derivative.expiration_date: The shares underlying these restricted stock units vest on June 6, 2020, subject to the Reporting Person's continuous service with the issuer as of the vesting date. Read SEC document
May 30, 2019 Filed May 31, 2019 00:37 UTC	LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447	Exercise / conversionRestricted Stock Unit · Derivative	2,915	$0.00	$0.00	Disclosure SEC source: 0001628280-19-007410 · wf-form4_155926304058506.xml · derivative · entry 2 Powell Andrew Kenneth William · CIK 0001304113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,915 shares Expires 2019-05-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis. F2 · shares: The restricted stock units were granted on January 30, 2019. F3 · derivative.exercise_date: The restricted stock units vested on May 30, 2019. F3 · derivative.expiration_date: The restricted stock units vested on May 30, 2019. Read SEC document
May 30, 2019 Filed May 31, 2019 00:37 UTC	LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447	Exercise / conversionCommon Stock	2,915	$9.91	$28,887.65	Disclosure SEC source: 0001628280-19-007410 · wf-form4_155926304058506.xml · nonDerivative · entry 1 Powell Andrew Kenneth William · CIK 0001304113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,915 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis. Read SEC document
May 28, 2019 Filed May 31, 2019 00:37 UTC	LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447	GrantRight to Buy Restricted Stock Unit (RSU) · Derivative	6,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001628280-19-007410 · wf-form4_155926304058506.xml · derivative · entry 3 Powell Andrew Kenneth William · CIK 0001304113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires not disclosed F1 · derivative.exercise_price: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis. F1 · price: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis. F4 · derivative.expiration_date: Restricted Stock Units will vest on the 1st anniversary of the grant date and will be automatically settled in shares of common stock. Read SEC document
January 30, 2019 Filed Feb 1, 2019 01:58 UTC	LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447	Exercise / conversionRight to Buy Restricted Stock Unit (RSU) · Derivative	2,915	Not disclosed	Not disclosed	Disclosure SEC source: 0001437749-19-001629 · rdgdoc.xml · derivative · entry 1 Powell Andrew Kenneth William · CIK 0001304113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,915 Underlying: Common Stock · 2,915 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis. F1 · price: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis. F2 · derivative.expiration_date: Restricted Stock Units will vest 4 months from the grant date and will be automatically settled in shares of common stock. Read SEC document
January 11, 2019 Filed Jan 14, 2019 19:25 UTC	LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447	PurchaseCommon Stock	525	$11.62	$6,100.50	Disclosure SEC source: 0001437749-19-000820 · rdgdoc.xml · nonDerivative · entry 1 Powell Andrew Kenneth William · CIK 0001304113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 Read SEC document
December 19, 2018 Filed Dec 21, 2018 16:07 UTC	Synthorx, Inc. THOR · Entity 152202	GrantStock Option (right to buy) · Derivative	27,015	$0.00 Strike: $14.00	$0.00	Disclosure SEC source: 0001209191-18-063891 · doc4.xml · derivative · entry 1 Powell Andrew Kenneth William · CIK 0001304113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,015 Underlying: Common Stock · 27,015 shares Expires 2028-12-18 F1 · derivative.exercise_date: The shares vest in equal monthly installments over a three year period such that the option is fully vested on December 19, 2021, subject to full vesting acceleration upon a change in control (as defined in Synthorx's equity incentive plan). Read SEC document
June 07, 2018 Filed Jun 8, 2018 16:02 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	GrantStock Option (right to buy) · Derivative	8,000	$0.00 Strike: $18.35	$0.00	Disclosure SEC source: 0001209191-18-036652 · doc4.xml · derivative · entry 1 Powell Andrew Kenneth William · CIK 0001304113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2028-06-06 F1 · shares: This grant was made pursuant to the issuer's non-employee director compensation policy. F2 · derivative.exercise_date: The shares underlying this option vest in twelve equal monthly installments through June 7, 2019, subject to the reporting person's continuous service as of such vesting date. Read SEC document
May 16, 2018 Filed May 17, 2018 19:34 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	PurchaseCommon Stock	500	$19.12	$9,560.00	Disclosure SEC source: 0001209191-18-031200 · doc4.xml · nonDerivative · entry 1 Powell Andrew Kenneth William · CIK 0001304113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500 Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.